High expression of GPR68, STAT3, TKTL1, RRM2, and TLR4 suggested a poor prognosis for GBM patients, while high expression of MPC1, SLC16A1, and MTOR indicated a long OS for patients. This evidence concerns the gene SLC16A1 and glioblastoma.